Dominik Bettenworth
YOU?
Author Swipe
View article: Variability and performance of radiologic stricture parameters in Crohn's disease: a systematic review and meta-analysis
Variability and performance of radiologic stricture parameters in Crohn's disease: a systematic review and meta-analysis Open
View article: ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 2
ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 2 Open
View article: Mucosal deficiency of mitochondria-driven humoral immunity is linked to Crohn’s Disease
Mucosal deficiency of mitochondria-driven humoral immunity is linked to Crohn’s Disease Open
Secretory IgA (SIgA) is critical for maintaining the intestinal barrier. A dysregulated B-cell compartment and altered Ig secretion have been well documented in Crohn’s disease (CD) patients, although their origin is unknown. To unravel th…
View article: Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline
Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline Open
Schlüsselwörter chronisch-entzündliche Darmerkrankungen - CED - Diagnose - Therapie - Remission - Remissionserhaltung
View article: ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment Open
View article: ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment Open
This article is the second in a series of two publications on the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn’s disease. The first article covers medical management; the present arti…
View article: Distinct metabolomic and lipidomic profiles in serum samples of patients with primary sclerosing cholangitis
Distinct metabolomic and lipidomic profiles in serum samples of patients with primary sclerosing cholangitis Open
Intoduction Identification of specific metabolome and lipidome profile of patients with primary sclerosing cholangitis (PSC) is crucial for diagnosis, targeted personalized therapy, and more accurate risk stratification. Methods Nuclear ma…
View article: A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice Open
View article: Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis Open
Subcutaneous infliximab showed a favorable efficacy profile for achieving clinical remission and endoscopic outcomes during maintenance treatment in CD or UC.
View article: P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series
P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series Open
Background Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease often necessitating liver transplantation (LTX). Approximately 70% of PSC patients have a concomitant diagnosis of inflammatory bowel diseas…
View article: P327 Profiling serum metabolome and lipidome to differentiate primary sclerosing cholangitis from Inflammatory Bowel Disease and healthy controls
P327 Profiling serum metabolome and lipidome to differentiate primary sclerosing cholangitis from Inflammatory Bowel Disease and healthy controls Open
Background Currently, the diagnosis of primary sclerosing cholangitis (PSC) is challenging due to a lack of specific biomarkers. Identification of a distinct metabolome and lipidome profile of PSC patients is crucial to facilitate diagnosi…
View article: Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn’s Disease and Ulcerative Colitis Compared With Healthy Control Individuals
Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn’s Disease and Ulcerative Colitis Compared With Healthy Control Individuals Open
Background Accurate biomarkers for disease activity and progression in patients with inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization and personalized therapy. We show that metabolic profiling of …
View article: Quantitative Phase Imaging Using Digital Holographic Microscopy to Assess the Degree of Intestinal Inflammation in Patients with Ulcerative Colitis
Quantitative Phase Imaging Using Digital Holographic Microscopy to Assess the Degree of Intestinal Inflammation in Patients with Ulcerative Colitis Open
Ulcerative colitis (UC) is characterized by chronic inflammation of the colorectum. Histological remission has emerged as a potential future treatment goal; however, the histopathological assessment of intestinal inflammation in UC remains…
View article: Intestinal MRI in Inflammatory Bowel Disease – Literature and Survey-Based Recommendations regarding Reporting by the German Radiological Society (DRG) and the German Competence Network for Inflammatory Bowel Diseases
Intestinal MRI in Inflammatory Bowel Disease – Literature and Survey-Based Recommendations regarding Reporting by the German Radiological Society (DRG) and the German Competence Network for Inflammatory Bowel Diseases Open
Background MR-enterography/enteroclysis (MRE) is increasingly used for primary diagnosis, detection of complications, and monitoring of patients with inflammatory bowel disease (IBD). Standardization of reporting is relevant to ensure qual…
View article: P270 A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease
P270 A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease Open
Background Small bowel fibrostenotic strictures are common in patients with Crohn’s disease (CD). No global consensus recommendations on definitions, diagnosis and clinical management are available. Methods Several systematic reviews follo…
View article: DOP82 Biological Treatment Cycles in Crohn’s Disease
DOP82 Biological Treatment Cycles in Crohn’s Disease Open
Background There are now a growing number of licensed biological therapies for patients with Crohn’s disease (CD) but given the costs of long-term maintenance treatment, as well as some concerns about potential side effects, there has been…
View article: P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis
P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis Open
Background Network meta-analysis (NMA) using randomised controlled trial (RCT) data can provide indirect evidence on comparative efficacy of various treatments.1 The NMA reported herein was conducted to evaluate infliximab (IFX) and vedoli…
View article: ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease
ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease Open
There are now a growing number of licensed biological therapies for patients with Crohn’s disease. However, there can be significant costs associated with long-term maintenance treatment, as well as some concerns about potential side-effec…
View article: Crossing barriers: the burden of inflammatory bowel disease across Western Europe
Crossing barriers: the burden of inflammatory bowel disease across Western Europe Open
An estimated 2.5–3 million individuals (0.4%) in Europe are affected by inflammatory bowel disease (IBD). Whilst incidence rates for IBD are stabilising across Europe, the prevalence is rising and subsequently resulting in a significant co…
View article: Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study
Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study Open
Purpose The clinical course of ulcerative colitis (UC) is highly heterogeneous, with 20 to 30% of patients experiencing chronic disease activity requiring immunosuppressive or biologic therapies. The aim of this study was to identify predi…
View article: Deficiency of the Two-Pore Potassium Channel KCNK9 Impairs Intestinal Epithelial Cell Survival and Aggravates Dextran Sodium Sulfate-Induced Colitis
Deficiency of the Two-Pore Potassium Channel KCNK9 Impairs Intestinal Epithelial Cell Survival and Aggravates Dextran Sodium Sulfate-Induced Colitis Open
View article: P053 The intestinal complement system and its role in dysregulation of the intestinal B-cell compartment in Crohn’s Disease patients
P053 The intestinal complement system and its role in dysregulation of the intestinal B-cell compartment in Crohn’s Disease patients Open
Background For several decades, there is growing evidence that a hyperactive B-cell compartment may be involved in the disturbed mucosal immune response in Crohn’s disease (CD) patients. This is reflected by approximately one third of all …
View article: Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial Open
View article: ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment Open
Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic inflammation extending to a variable extent from the rectum. Care of the patient with UC requires appropriate input from across the multiprofess…
View article: ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment Open
This is the second of a series of two articles reporting the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of adult patients with ulcerative colitis [UC]. The first article is focused on medica…
View article: Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases
Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases Open
Intestinal fibrosis is considered an inevitable complication of Crohn’s disease (CD) that results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment is required to treat the majority of patients. Progress …
View article: Soluble syndecan-1 as marker of intestinal inflammation: A preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis
Soluble syndecan-1 as marker of intestinal inflammation: A preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis Open
Serum soluble Sdc1 correlates significantly with mucosa inflammation and Mayo score in UC. Clinical trials No. NCT02333526.
View article: Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn’s Disease: A Systematic Review
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn’s Disease: A Systematic Review Open
View article: International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease
International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease Open
Objective Effective medical therapy and validated trial outcomes are lacking for small bowel Crohn’s disease (CD) strictures. Histopathology of surgically resected specimens is the gold standard for correlation with imaging techniques. How…
View article: Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn’s Disease: A Potentially Novel Mesenteric Creeping Fat Index
Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn’s Disease: A Potentially Novel Mesenteric Creeping Fat Index Open
Background and Aims Emerging evidence points to a link between creeping fat and the pathogenesis of Crohn’s disease [CD]. Non-invasive assessment of the severity of creeping fat on cross-sectional imaging modality has seldom been investiga…